Serena Williams at the Prelude to the 2024 Paris Olympics (Aurore Marechal/Abaca/Sipa USA via AP Images)
September 11, 2024 02:54 PM EDTUpdated 03:13 PM
Pharma
FDA+
Marketing

FDA crit­i­cizes Ab­b­Vie's 'mis­lead­ing' ad with Ser­e­na Williams

Zachary Brennan

Senior Editor

The FDA’s Of­fice of Pre­scrip­tion Drug Pro­mo­tion sent a let­ter to Ab­b­Vie late last month, call­ing out the com­pa­ny for what it said was a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times